183 related articles for article (PubMed ID: 17284087)
1. Selegiline transdermal system: in the treatment of major depressive disorder.
Frampton JE; Plosker GL
Drugs; 2007; 67(2):257-65; discussion 266-7. PubMed ID: 17284087
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
Amsterdam JD
J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
[TBL] [Abstract][Full Text] [Related]
3. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS
J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821
[TBL] [Abstract][Full Text] [Related]
4. Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
Patkar AA; Pae CU; Masand PS
CNS Spectr; 2006 May; 11(5):363-75. PubMed ID: 16641841
[TBL] [Abstract][Full Text] [Related]
5. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
Amsterdam JD; Bodkin JA
J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
[TBL] [Abstract][Full Text] [Related]
6. Transdermal selegiline.
Patkar AA; Pae CU; Zarzar M
Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
[TBL] [Abstract][Full Text] [Related]
7. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
Bodkin JA; Amsterdam JD
Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
[TBL] [Abstract][Full Text] [Related]
8. Selegiline transdermal system: a novel treatment option for major depressive disorder.
Nandagopal JJ; DelBello MP
Expert Opin Pharmacother; 2009 Jul; 10(10):1665-73. PubMed ID: 19527191
[TBL] [Abstract][Full Text] [Related]
9. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).
Jang S; Jung S; Pae C; Kimberly BP; Craig Nelson J; Patkar AA
J Affect Disord; 2013 Dec; 151(3):854-9. PubMed ID: 24021959
[TBL] [Abstract][Full Text] [Related]
10. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
Robinson DS; Amsterdam JD
J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687
[TBL] [Abstract][Full Text] [Related]
11. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
[TBL] [Abstract][Full Text] [Related]
12. Transdermal selegiline (Emsam).
Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
[No Abstract] [Full Text] [Related]
13. A critical appraisal of the selegiline transdermal system for major depressive disorder.
Bied AM; Kim J; Schwartz TL
Expert Rev Clin Pharmacol; 2015; 8(6):673-81. PubMed ID: 26427518
[TBL] [Abstract][Full Text] [Related]
14. Transdermal selegiline and intravenous cocaine: safety and interactions.
Houtsmuller EJ; Notes LD; Newton T; van Sluis N; Chiang N; Elkashef A; Bigelow GE
Psychopharmacology (Berl); 2004 Feb; 172(1):31-40. PubMed ID: 14605792
[TBL] [Abstract][Full Text] [Related]
15. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
[TBL] [Abstract][Full Text] [Related]
16. MAO inhibitors: risks, benefits, and lore.
Wimbiscus M; Kostenko O; Malone D
Cleve Clin J Med; 2010 Dec; 77(12):859-82. PubMed ID: 21147941
[TBL] [Abstract][Full Text] [Related]
17. Monoamine oxidase inhibitors: a new generation.
Robinson DS
Psychopharmacol Bull; 2002; 36(3):124-38. PubMed ID: 12473970
[TBL] [Abstract][Full Text] [Related]
18. Translating the evidence on atypical depression into clinical practice.
Hyman Rapaport M
J Clin Psychiatry; 2007; 68 Suppl 3():31-6. PubMed ID: 17348765
[TBL] [Abstract][Full Text] [Related]
19. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.
Clayton AH; Campbell BJ; Favit A; Yang Y; Moonsammy G; Piontek CM; Amsterdam JD
J Clin Psychiatry; 2007 Dec; 68(12):1860-6. PubMed ID: 18162016
[TBL] [Abstract][Full Text] [Related]
20. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues.
Mawhinney M; Cole D; Azzaro AJ
J Pharm Pharmacol; 2003 Jan; 55(1):27-34. PubMed ID: 12625864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]